机译:利巴韦林在48周聚乙二醇化干扰素-α2b联合利巴韦林治疗慢性丙型肝炎的后期浓度可用于预测病毒学应答
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan;
机译:对于慢性丙型肝炎,在48周聚乙二醇化干扰素-α2b加利巴韦林治疗的后期,利巴韦林的浓度可用于预测病毒学应答。
机译:聚乙二醇化干扰素-α2a和利巴韦林与聚乙二醇化干扰素-α2b和利巴韦林在慢性丙型肝炎中的荟萃分析。
机译:高龄不是慢性丙型肝炎病毒患者对聚乙二醇干扰素-α和利巴韦林治疗的病毒学应答的阴性预测因素
机译:胸腺素α1联合聚乙二醇化干扰素α2a和利巴韦林治疗慢性丙型肝炎无反应者的研究
机译:接受聚乙二醇干扰素和利巴韦林抗病毒治疗的慢性丙型肝炎退伍军人依从性的含义。
机译:预测感染丙型肝炎病毒基因型4的患者对聚乙二醇化干扰素α-2a和利巴韦林48周疗程的持续病毒学应答
机译:预测感染丙型肝炎病毒基因型4的患者对聚乙二醇化干扰素α-2a和利巴韦林48周疗程的持续病毒学应答